Millenium: The Takeda Oncology Company


Millennium Pharmaceuticals, Inc., The Takeda Oncology Company is a leading biopharmaceutical company. The Company markets Velcade for injection, a cancer product, and has a growing clinical development pipeline of product candidates.

“Informatica is helping to transform Millennium into a more dynamic and responsive healthcare organization. With Salesforce integrated seamlessly with our operational systems, we’re moving closer to our customers to best interpret their needs and deliver the service and care they expect.”

— Sue Corwin, Associate Director, Commercial & Business Systems, Millennium: The Takeda Oncology Company


Business Need

Improve business agility.

Accelerate and streamline decision-making.

Improve operational efficiency for competitive advantage.



Lack of a standard platform that supported connectivity to a variety of source and target types, such as Oracle DB, XML, Web Service, and salesforce.com.

Reliance on localized solutions using ETL, PL/SQL, Java, Perl, SQR, and other scripting languages.

Existing integration solution difficult to support and to manage resources effectively.


Solutions & Results

Reduced IT costs.

Increased developer productivity.

Ease of use, leveraging benefits of SaaS platform.


Products & Services

Informatica PowerCenter

Accesses, integrates, and delivers any and all data quickly and cost-effectively, without hand coding.

Informatica PowerExchange for Salesforce CRM

Accesses mission-critical data and delivers it throughout the enterprise wherever it’s needed, on any schedule.

Success Stories

M.D. Anderson Cancer Center

Informatica empowered scientific and clinical collaboration at this renowned cancer center by turning data into knowledge and facilitating self-service business intelligence.


Leading life sciences company uses Informatica PowerCenter to improve early detection of R&D issues, decrease time-to-market and ensure researchers have timely access to data.


IQVIA gained enhanced data accuracy, timeliness, and completeness and faster time to market for its pharmaceuticals.